In the second in a two-part series, the Pharmacy Guild's Trent Twomey discusses the need for reform of opiate dependence therapy, out-of-pocket costs and expresses concern over the challenge companies face in navigating the PBS-listing process.
Guild's Trent Twomey on costs and the access challenge
April 8, 2021 Latest NewsBioPharmaBioPharmaDispatch Executive
Latest Video
New Stories
-
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
US childhood vaccine move away from combinations contrasts with Australia’s national schedule
August 12, 2026 - - Latest News -
Former minister joins DBG Health board as company broadens healthcare ambition
August 12, 2026 - - Latest News -
A sage appointment that puts DBG Health another step closer to a serious understanding of decision-making
August 12, 2026 - - Latest News -
Patients welcome the timely PBS listing of rare cancer therapy
August 12, 2026 - - Latest News -
How education exposes the moral and ethical limits of our health decision-making
August 11, 2026 - - Latest News

